Clinical trials
Advanced Esophageal Carcinoma clinical trials
Below are recruiting advanced esophageal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 196 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07403136RecruitingPhase 2
Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT07567716Enrolling by invitation
Study of How Advanced Esophageal Cancer Spreads After Surgery
This research examines tissue samples from patients who had surgery to remove advanced esophageal cancer in the neck or chest area. The study aims to understand how the cancer invaded surrounding tissues, which may help doctors better treat similar patients in the future.
ShanghaiAges Any age - NCT04519905Recruiting
Testing two ways of radiation in older esophagus cancer patients
This study compares a planned radiation approach given at the same time as other treatment for older adults with esophageal squamous cell carcinoma. It may help find a safer and more effective radiation schedule for people who are fit enough for treatment.
Nanjing, JiangsuAges 76 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Orlando, FloridaAges 18 years+ - NCT04280822RecruitingPhase 3
Immunotherapy plus chemo versus chemo alone before surgery
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
Zhengzhou, HenanAges 18–75 - NCT06819566RecruitingPhase 2
Preventing bleeding from enlarged veins in the esophagus
This study tests whether tying off high-risk veins in the esophagus before starting a common liver cancer treatment can prevent bleeding. It is for people with liver cancer that has spread but who have never had cancer treatment before.
Seoul, Song-paAges 19–80 - NCT05760391Recruiting
Check anti-PD-1 therapy plus radiation for advanced esophageal cancer
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
ShanghaiAges 18–80 - NCT06601309RecruitingPhase 2
Study of treatments before surgery for esophageal cancer
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Fuzhou, FujianAges 18–75 - NCT06609863Recruiting
Triple therapy for large liver cancer tumors
This trial tests combining a special type of chemo delivered directly to the liver (dTACE-HAIC) with two immunotherapy drugs (bevacizumab and atezolizumab) for people with huge liver cancer tumors (10 cm or larger). The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, None SelectedAges 18–75 - NCT07246668RecruitingPhase 2
Carbon ion radiation with immunotherapy for advanced liver cancer
This trial tests a combination of carbon ion radiation therapy with two drugs, atezolizumab and bevacizumab, for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT06596954Recruiting
Lymphocyte-sparing radiation for esophageal cancer
This trial tests a special type of radiation therapy that aims to spare your immune cells (lymphocytes) while treating esophageal cancer. It may help patients with locally advanced esophageal squamous cell carcinoma who are in good overall health.
Shanghai, ChinaAges 18–80 - NCT07061704RecruitingPhase 1/Phase 2
Oncolytic virus trial for esophageal cancer
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
Chengdu, SichuanAges 18–80 - NCT02297217RecruitingPhase 2
Chemoradiation for advanced esophagus cancer that can’t be cured
This trial studies whether a combination of chemotherapy and radiation can help people with advanced esophageal cancer who cannot have curative treatment. It focuses on people who are having swallowing trouble and may be able to start treatment soon.
Calgary, AlbertaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT04807673RecruitingPhase 3
Pembrolizumab before surgery versus chemoradiation for esophageal cancer
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07457528RecruitingPhase 2
Chemo, radiation, and immune therapy before surgery for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05281003RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before surgery can improve outcomes for people with locally advanced, operable esophageal squamous cell carcinoma. It may help shrink the tumor and improve the chance of successful surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+
Hear when a new Advanced Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced esophageal carcinoma?
- Yes. Clin2 currently lists 196 recruiting advanced esophageal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced esophageal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced esophageal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.